Vapotherm Reports Second Quarter 2024 Financial Results

$VAPO
Medical/Dental Instruments
Health Care
Get the next $VAPO alert in real time by email

EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights.

Second Quarter 2024 Financial Results and Related Highlights

  • Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023
    • Disposables revenue increased by 13.9% as compared to the second quarter of 2023
    • U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023
  • Gross margin in the second quarter of 2024 was 49.1% as compared to 42.8% in the second quarter of 2023
  • For the second quarter of 2024, GAAP operating expenses were $17.6 million and non-GAAP cash operating expenses, as defined below, were $12.1 million
    • GAAP operating expenses increased by $0.5 million from the second quarter of 2023
    • Non-GAAP cash operating expenses decreased by $2.1 million from the second quarter of 2023
  • Adjusted EBITDA loss in the second quarter of 2024 was $2.9 million as compared to an Adjusted EBITDA loss of $6.4 million in the second quarter of 2023
  • The Company's unrestricted cash and cash equivalents were $2.9 million at the end of the second quarter of 2024

"I'm pleased our U.S. disposables revenue grew by nearly 26% over the second quarter of 2023 and our worldwide disposables revenue grew by nearly 14% over the same period," said Joseph Army, President and CEO. "We are seeing increased adoption of our technology on COPD patients since the results of the HYPERACT study were presented at the 2024 Critical Care Congress."

Results for the Three Months Ended June 30, 2024

The following table reflects the Company's net revenue for the three months ended June 30, 2024 and 2023:





Three Months Ended June 30,



















2024





2023





Change







(in thousands, except percentages)







Amount





% of Revenue





Amount





% of Revenue





$





%



Revenue





































Capital (product & lease revenue)



$

3,061







18.1

%



$

3,646







22.7

%



$

(585)







(16.0)

%

Disposables





12,442







73.7

%





10,927







68.1

%





1,515







13.9

%

Service and other





1,381







8.2

%





1,464







9.2

%





(83)







(5.7)

%

Total net revenue



$

16,884







100.0

%



$

16,037







100.0

%



$

847







5.3

%

Net revenue for the second quarter of 2024 was $16.9 million and increased 5.3% over the second quarter of 2023 primarily due to U.S. disposables revenue growth of 25.9% over the second quarter of 2023, which was driven by increased unit volume and adoption of the Company's HVT 2.0 platform.

Revenue information by geography is summarized as follows:





Three Months Ended June 30,



















2024





2023





Change







(in thousands, except percentages)







Amount





% of Revenue





Amount





% of Revenue





$





%



United States



$

13,323







78.9

%



$

11,847







73.9

%



$

1,476







12.5

%

International





3,561







21.1

%





4,190







26.1

%





(629)







(15.0)

%

Total net revenue



$

16,884







100.0

%



$

16,037







100.0

%



$

847







5.3

%

Net revenue in the United States for the second quarter of 2024 was $13.3 million and increased 12.5% over the second quarter of 2023 primarily due to U.S. disposables revenue growth. Net revenue in International markets for the second quarter of 2024 was $3.6 million and decreased 15.0% over the second quarter of 2023 due to a decrease in disposables revenue in distributor markets.

Gross profit and gross margin for the second quarter of 2024 was $8.3 million and 49.1%, respectively, as compared to gross profit of $6.9 million and gross margin of 42.8% for the second quarter of 2023. The increases in gross profit and gross margin were primarily due to the improved efficiency of our Mexico operation.

Total operating expenses were $17.6 million in the second quarter of 2024, an increase of $0.5 million as compared to the second quarter of 2023. Non-GAAP cash operating expenses, which exclude merger-related costs, gain on disposal of property and equipment, depreciation and amortization, stock-based compensation expense, and gain from deconsolidation were $12.1 million in the second quarter of 2024 compared to $14.2 million in the second quarter of 2023. The increase in operating expenses was primarily due to merger-related costs, partially offset by the Company's Path to Profitability initiatives. The decrease in non-GAAP cash operating expenses was primarily due to the Company's Path to Profitability initiatives.

Net loss for the second quarter of 2024 was $14.3 million, or $2.22 per share, compared to $14.8 million, or $2.34 per share, in the second quarter of 2023. Net loss per share was based on 6,442,763 and 6,328,222 weighted average shares outstanding for the second quarter of 2024 and 2023, respectively.

Adjusted EBITDA was negative $2.9 million for the second quarter of 2024 as compared to negative $6.4 million for the second quarter of 2023. The reduction in Adjusted EBITDA loss was primarily due to the Company's Path to Profitability initiatives.

Cash Position

Unrestricted cash and cash equivalents were $2.9 million as of June 30, 2024 compared to $9.7 million as of December 31, 2023.

Website Information

Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http:// investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm's disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm's website, in addition to following Vapotherm's press releases, Securities and Exchange Commission ("SEC") filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm's website is not incorporated by reference into, and is not a part of, this document.

Non-GAAP Financial Measures

This press release includes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, non-GAAP operating expenses and non-GAAP cash operating expenses. EBITDA and Adjusted EBITDA differ from net income as calculated in accordance with U.S. generally accepted accounting principles ("GAAP") and non-GAAP operating expenses and non-GAAP cash operating expenses differ from operating expenses as calculated in accordance with GAAP. EBITDA represents net loss less interest expense, net, income tax provision or benefit, and depreciation and amortization, and Adjusted EBITDA represents EBITDA as further adjusted for the merger-related costs, impact of foreign currency (loss) gain, stock-based compensation expense, gain from deconsolidation and gain on disposal of property and equipment. Non-GAAP operating expenses is calculated by excluding from GAAP operating expenses merger-related costs, gain on disposal of property and equipment, and non-GAAP cash operating expenses is calculated by further excluding additional items, including stock-based compensation expense, depreciation and amortization, and gain from deconsolidation. The Company has reconciled all historical non-GAAP financial measures with the most directly comparable GAAP financial measures in tables accompanying this release.

These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures, as measures of the Company's operating performance and for planning purposes, including the preparation of the Company's annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period.

These non-GAAP financial measures should not be considered alternatives to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our capital expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in the Adjusted EBITDA presentation. The Company's presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company's GAAP results in addition to using Adjusted EBITDA and other non-GAAP financial measures on a supplemental basis. The Company's definitions of Adjusted EBITDA, non-GAAP operating expenses and non-GAAP cash operating expenses are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

About Vapotherm

Vapotherm, Inc. (OTCQX:VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 4.5 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems' mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including the statement about the Company's belief regarding an increased willingness to use the Company's technology on COPD patients. In some cases, you can identify forward-looking statements by terms such as "believe," "expect," "continue," "plan," "intend," "will," "outlook," or "typically," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm's proposed merger with Veronica Merger Sub, Inc. and Vapotherm's ability to satisfy the conditions to closing or otherwise complete the merger on a timely basis or at all and the impact the pending merger may have on Vapotherm's current plans and operations, including potentially diverting management's attention from our business; the effects of the merger (or the announcement or pendency thereof) on Vapotherm's future business and financial and operating results, its ability to retain key personnel and maintain relationships with customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities, and the risk and outcome of legal proceedings related to the merger; Vapotherm's ability to raise additional capital to fund its existing operations and debt service obligations; Vapotherm's ability to comply with its financial covenants, execute on its path to profitability initiative, convert excess inventory into cash and fund its business and otherwise continue as a going concern through 2024; Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future; risks associated with its manufacturing operations in Mexico; Vapotherm's dependence on sales generated from its High Velocity Therapy systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability for High Velocity Therapy systems to gain increased market acceptance; Vapotherm's inexperience directly marketing and selling its products; the potential loss of one or more suppliers and dependence on its new third party manufacturer; Vapotherm's susceptibility to seasonal fluctuations; Vapotherm's failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or other intellectual property protection for its products; the impact of COVID on its business, including its supply chain; risks in holding Vapotherm stock in light of trading on the OTCQX tier of the OTC Markets; and the other risks and uncertainties included under the heading "Risk Factors" in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and subsequent SEC reports. The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

 

VAPOTHERM, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)











June 30, 2024





December 31, 2023







(unaudited)









Assets













Current assets













Cash and cash equivalents



$

2,904





$

9,725



Accounts receivable, net of expected credit losses

   of $240 and $160, respectively





8,563







10,672



Inventories, net





23,295







22,968



Prepaid expenses and other current assets





2,259







3,058



Total current assets





37,021







46,423



Property and equipment, net





23,592







23,703



Operating lease right-of-use assets





2,911







3,372



Restricted cash





1,109







1,109



Goodwill





561







565



Deferred income tax assets





56







57



Other long-term assets





2,677







2,388



Total assets



$

67,927





$

77,617



Liabilities and Stockholders' Deficit













Current liabilities













Accounts payable



$

4,381





$

5,053



Contract liabilities





1,258







1,237



Accrued expenses and other current liabilities





22,913







12,805



Current portion of loans payable, net





118,406







-



Total current liabilities





146,958







19,095



Long-term loans payable, net





-







107,059



Other long-term liabilities





2,288







6,797



Total liabilities





149,246







132,951



Commitments and contingencies













Stockholders' deficit













Preferred stock ($0.001 par value) 25,000,000 shares authorized; no shares

   issued and outstanding as of June 30, 2024 and December 31, 2023





-







-



Common stock ($0.001 par value) 21,875,000 shares authorized as of

   June 30, 2024 and December 31, 2023, 6,241,958 and 6,165,806

   shares issued and outstanding as of June 30, 2024 and

   December 31, 2023, respectively





6







6



Additional paid-in capital





496,083







492,764



Accumulated other comprehensive (loss) income





(106)







91



Accumulated deficit





(577,302)







(548,195)



Total stockholders' deficit





(81,319)







(55,334)



Total liabilities and stockholders' deficit



$

67,927





$

77,617



 

VAPOTHERM, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)











Three Months Ended June 30,





Six Months Ended June 30,







2024





2023





2024





2023







(unaudited)





(unaudited)



Net revenue



$

16,884





$

16,037





$

36,018





$

33,768



Cost of revenue





8,601







9,177







18,078







20,696



Gross profit





8,283







6,860







17,940







13,072



Operating expenses

























Research and development





3,328







3,723







6,960







7,710



Sales and marketing





6,732







8,276







13,874







17,868



General and administrative





3,768







5,019







8,240







10,789



Merger-related costs





3,723







-







3,723







-



Impairment of right-of-use assets





-







-







-







432



(Gain) loss on disposal of property and equipment





(1)







(2)







(9)







53



Total operating expenses





17,550







17,016







32,788







36,852



Loss from operations





(9,267)







(10,156)







(14,848)







(23,780)



Other (expense) income

























Interest expense





(4,944)







(4,642)







(14,197)







(8,973)



Interest income





1







26







6







54



Foreign currency (loss) gain





(43)







9







(39)







(145)



Net loss before income taxes



$

(14,253)





$

(14,763)





$

(29,078)





$

(32,844)



Provision for income taxes





18







25







29







34



Net loss



$

(14,271)





$

(14,788)





$

(29,107)





$

(32,878)



Other comprehensive (loss) income:

























Foreign currency translation adjustments





(35)







(22)







(197)







113



Total other comprehensive (loss) income





(35)







(22)







(197)







113



Total comprehensive loss



$

(14,306)





$

(14,810)





$

(29,304)





$

(32,765)



Net loss per share - basic and diluted



$

(2.22)





$

(2.34)





$

(4.52)





$

(5.76)



Weighted-average number of shares used in calculating net

   loss per share, basic and diluted (1)





6,442,763







6,328,222







6,436,631







5,705,607





(1) On August 18, 2023, the Company effected a 1:8 reverse stock split for each share of common stock issued

and outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split.

 

VAPOTHERM, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)







Six Months Ended June 30,







2024





2023



Cash flows from operating activities













Net loss



$

(29,107)





$

(32,878)



Adjustments to reconcile net loss to net cash used in operating activities













Stock-based compensation expense





3,290







5,405



Depreciation and amortization





2,528







2,445



Provision for credit losses





110







(2)



Provision for inventory valuation





73







283



Non-cash lease expense





461







733



Impairment of right-of-use assets





-







432



(Gain) loss on disposal of property and equipment





(9)







53



Placed units reserve





234







418



Interest paid in-kind





4,918







4,553



Non-cash interest expense





4,931







620



Amortization of discount on debt





429







368



Deferred income taxes





29







34



Changes in operating assets and liabilities:













Accounts receivable





1,986







212



Inventories





(407)







7,646



Prepaid expenses and other assets





506







(2,794)



Accounts payable





(579)







(315)



Contract liabilities





23







72



Accrued expenses and other liabilities





2,045







(3,460)



Operating lease liabilities, current and long-term





(1,288)







(1,213)



Net cash used in operating activities





(9,827)







(17,388)



Cash flows from investing activities













Purchases of property and equipment





(2,662)







(1,408)



Net cash used in investing activities





(2,662)







(1,408)



Cash flows from financing activities













Proceeds from issuance of common stock and pre-funded warrants and

   accompanying warrants in private placement, net of issuance costs





-







20,943



Proceeds from loans, net of discount





5,820







-



Proceeds from exercise of warrants





-







3



Proceeds from exercise of stock options





1







-



Proceeds from issuance of common stock under Employee Stock Purchase Plan





12







77



Net cash provided by financing activities





5,833







21,023



Effect of exchange rate changes on cash, cash equivalents and restricted cash





(165)







35



Net (decrease) increase in cash, cash equivalents and restricted cash





(6,821)







2,262



Cash, cash equivalents and restricted cash













Beginning of period





10,834







16,847



End of period



$

4,013





$

19,109



Supplemental disclosures of cash flow information













Interest paid during the period



$

3,557





$

2,720



Property and equipment purchases in accounts payable and accrued expenses



$

732





$

175



Issuance of common stock warrants in conjunction with long term debt



$

16





$

71



Issuance of common stock for services



$

155





$

117



Non-GAAP Financial Measures

The following table contains a reconciliation of net loss to Adjusted EBITDA for the three months ended June 30, 2024 and 2023, respectively.





Three Months Ended June 30,







2024





2023



(Unaudited)



(in thousands)



Net loss



$

(14,271)





$

(14,788)



Interest expense, net





4,943







4,616



Provision for income taxes





18







25



Depreciation and amortization





1,224







1,197



EBITDA



$

(8,086)





$

(8,950)



Merger-related costs





3,723







-



Stock-based compensation





1,456







2,585



Foreign currency loss (gain)





43







(9)



Gain from deconsolidation





-







(5)



Gain on disposal of property and equipment





(1)







(2)



Adjusted EBITDA



$

(2,865)





$

(6,381)



The following table contains a reconciliation of operating expenses to Non-GAAP operating expenses and Non-GAAP cash operating expenses for the three months ended June 30, 2024 and June 30, 2023, respectively.





Three Months Ended June 30,







2024





2023



(Unaudited)



(in thousands)



GAAP operating expenses



$

17,550





$

17,016



Merger-related costs





(3,723)







-



Gain on disposal of property and equipment





1







2



Non-GAAP operating expenses





13,828







17,018



Stock-based compensation





(1,423)







(2,534)



Depreciation and amortization





(262)







(293)



Gain from deconsolidation





-







5



Non-GAAP cash operating expenses



$

12,143





$

14,196



 

Supplemental Operating Metrics





June 30,

















2024





2023





Change





Amount





Amount





Amount





%



HVT 2.0 and precision flow units installed base























United States



24,992







24,563







429







1.7

%

International



12,975







12,729







246







1.9

%

Total



37,967







37,292







675







1.8

%



























Three Months Ended June 30,

















2024





2023





Change





Amount





Amount





Amount





%



HVT 2.0 and precision flow units sold and leased























United States



193







293







(100)







(34.1)

%

International



99







146







(47)







(32.2)

%

Total



292







439







(147)







(33.5)

%

























Disposable patient circuits sold























United States



82,290







69,323







12,967







18.7

%

International



29,634







35,744







(6,110)







(17.1)

%

Total



111,924







105,067







6,857







6.5

%

























 

Investor Relations Contacts:

John Landry, SVP & CFO, ir@vtherm.com, +1 (603) 658-0011

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vapotherm-reports-second-quarter-2024-financial-results-302220359.html

SOURCE Vapotherm, Inc.

Get the next $VAPO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VAPO

DatePrice TargetRatingAnalyst
5/6/2022$12.00 → $5.00Buy → Hold
Canaccord Genuity
4/7/2022$23.00 → $8.00Overweight → Underweight
Piper Sandler
More analyst ratings

$VAPO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Vapotherm Announces Closing of Merger

    EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

    $VAPO
    Medical/Dental Instruments
    Health Care
  • Vapotherm Reports Second Quarter 2024 Financial Results

    EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

    $VAPO
    Medical/Dental Instruments
    Health Care
  • Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

    EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

    $VAPO
    Medical/Dental Instruments
    Health Care

$VAPO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VAPO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$VAPO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VAPO
SEC Filings

See more

$VAPO
Leadership Updates

Live Leadership Updates

See more
  • Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

    TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

    $IART
    $VAPO
    Medical/Dental Instruments
    Health Care
  • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

$VAPO
Financials

Live finance-specific insights

See more
  • Vapotherm To Report Second Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

    $VAPO
    Medical/Dental Instruments
    Health Care
  • Vapotherm Reports First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

    $VAPO
    Medical/Dental Instruments
    Health Care
  • Vapotherm To Report First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

    $VAPO
    Medical/Dental Instruments
    Health Care

$VAPO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more